Pie Medical Imaging Launches AI-Powered Echocardiography Platform
CAAS Qardia 2.0, an updated version of the CAAS Qardia echocardiography software platform, reportedly incorporates artificial intelligence (AI)-enabled workflows, and provides enhanced imaging and analysis of key cardiac measures.
Combining off-cart echocardiography analysis with artificial intelligence (AI) capabilities, Pie Medical Imaging has launched the FDA-cleared CAAS Qardia 2.0 platform.
An update to the company’s CAAS Qardia echocardiography software, the CAAS Qardia 2.0 software offers robust visualization of stress-echo imaging and diastolic function, and reportedly excels at analysis of myocardial strain and other cardiac assessments, according to Pie Medical Imaging.
The company notes that quality control indices with the CAAS Qardia 2.0 platform enable clinicians to counteract potential foreshortening of cardiac imaging that may impact measurements such as myocardial strain. Leveraging AI-powered workflows, the CAAS Qardia 2.0 software generates automated reporting of key parameters.
Pie Medical imaging adds that the CAAS Qardia software can be server-based with access from any PC within a hospital network or be deployed in a stand-alone setup.
(Editor's note: For a related article, see "FDA Clears AI-Powered Echocardiography Platform for Detecting Heart Failure with Preserved Ejection Fraction.")
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
